Related Experiment Videos
Clopidogrel in interventional cardiology: questions answered and questions remaining
Janarthan Y Nikhil1, Sam Radhakrishnan, Fran L Paradiso-Hardy
1Schulich Heart Program and Department of Pharmacy, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario.
Insights
Clopidogrel is a suitable alternative to ticlopidine for patients undergoing percutaneous coronary intervention (PCI) when combined with acetylsalicylic acid. It offers similar effectiveness in preventing cardiac events with reduced risk of blood disorders.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Ticlopidine and clopidogrel are antiplatelet agents used with acetylsalicylic acid (ASA) in percutaneous coronary intervention (PCI).
- Thrombotic thrombocytopenic purpura (TTP) is a rare but serious adverse event associated with both agents.
- Optimizing antiplatelet therapy is crucial for preventing stent thrombosis and vascular events post-PCI.
Purpose of the Study:
- To evaluate clopidogrel as a replacement for ticlopidine in combination with ASA for PCI.
- To compare the efficacy and safety profiles of clopidogrel and ticlopidine.
- To assess the optimal dosing strategy and long-term implications of clopidogrel therapy post-PCI.
Main Methods:
- Comparative analysis of clopidogrel and ticlopidine efficacy in reducing adverse cardiac events.
- Assessment of hematological toxicity associated with both antiplatelet agents.
- Review of clinical data regarding thrombotic stent occlusion and hemorrhagic complications.
Main Results:
- Clopidogrel demonstrates comparable efficacy to ticlopidine in preventing adverse cardiac events post-PCI.
- Clopidogrel exhibits a lower risk of hematological toxicity compared to ticlopidine.
- A 300 mg loading dose of clopidogrel before PCI is recommended for rapid platelet inhibition to mitigate early stent thrombosis.
- Recent clopidogrel use increases hemorrhagic risk during bypass surgery.
- Ongoing trials are investigating the long-term benefits of clopidogrel in reducing late stent occlusion and vascular events.
Conclusions:
- Clopidogrel is an appropriate and safer alternative to ticlopidine for dual antiplatelet therapy with ASA in PCI.
- Optimal loading dose strategy for clopidogrel is essential for immediate therapeutic effect.
- Careful consideration of clopidogrel's impact on perioperative bleeding, especially in bypass surgery, is warranted.
- Long-term clopidogrel therapy holds promise for sustained vascular protection post-PCI.
Abstract:
Clopidogrel is appropriate as a replacement for ticlopidine when used in combination with acetylsalicylic acid in the setting of percutaneous coronary intervention (PCI). Compared with ticlopidine, clopidogrel has comparable efficacy in reducing adverse cardiac events and a lower risk of hematological toxicity; both medications have been associated with rare cases of the very serious syndrome of thrombotic thrombocytopenic purpura. Clopidogrel should preferably be initiated with a loading dose of 300 mg before PCI, because most cases of thrombotic stent occlusion occur shortly after stent implantation, and attainment of target platelet inhibition is delayed for several days if a loading dose is not given. Bypass surgery in patients recently treated with clopidogrel appears to be associated with a significant increase in hemorrhagic complications. Long term therapy with clopidogrel after PCI may decrease late thrombotic stent occlusion and late vascular events; this hypothesis is currently being evaluated in randomized trials. By inhibiting platelet activation, clopidogrel may have a mechanism of benefit that is independent of the potent inhibition of platelet aggregation produced by the glycoprotein IIb/IIIa inhibitors.